A lack of access to capital, particularly proof-of-concept funding, is stifling growth in the UK’s university spinout sector, according to a recent survey conducted by Symbiosis IP, a part of professional services group Gateley.

Described by one respondent as a “broken funding model”, the sector’s lack of funding and difficulty securing much-needed investment capital, particularly outside of the South East, are two of the most urgent issues facing the university spinout sector.

AMSBIO announce a new range of Synthetic Nanodiscs that enable preparation of multi-pass transmembrane proteins in their active form, revolutionizing the future of membrane protein research and drug development. Membrane Proteins account for more than 60% of all FDA-approved drug targets and 90% of antibody-based drug targets. Many traditional sample preparation methods struggle with challenges in obtaining water-soluble and bioactive forms of multi-pass transmembrane proteins.

Recent top global hires for large-cap, mid-cap, and public companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech in the second half of 2024.

CEO/ C-suite/ Board

Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.

Cambridge, UK: o2h discovery is pleased to announce the launch of o2h Biology Match Funding award, a unique programme aimed at accelerating drug discovery research by offering to match fund 50% of the cost for biology research projects up to $65K/£50K in value. This initiative presents an exciting opportunity for biotechs of all sizes and pharma to achieve key scientific milestones, helping to advance their drug discovery programmes.

03 December 2024, London - A message from Dr Rich Ferrie – CEO, LBIC

LBIC is evolving. A lot has changed since we opened as London’s first bio-incubator over 24 years ago.

Today, we’re at a pivotal moment in our history, entering a new phase of growth as we expand into the Apex Building and continue to evolve within the dynamic life sciences landscape.